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Objectives Valve hemodynamics and clinical outcomes among patients with a small aortic annulus who underwent trans-
catheter aortic valve implantation (TAVI) were examined.
Background The presence of a small aortic annulus may complicate the surgical management of patients with severe aortic
stenosis (AS). TAVI is an alternative to aortic valve replacement (AVR) in high-risk patients, but few data exist on
the results of TAVI in patients with a small aortic annulus.
Methods Between 2007 and 2010, 35 patients (mean age 79.2  9.4 years) with severe AS and an aortic annulus diam-
eter 20 mm (mean 18.5  0.9 mm) underwent TAVI with a 23-mm Edwards SAPIEN bioprosthesis (Edwards
Lifesciences, Inc., Irvine, California). Echocardiographic parameters and clinical outcomes were assessed prior to
discharge and at 6, 12, and 24 months.
Results Procedural success was achieved in 34 patients (97.1%). There was 1 in-hospital death. Peak and mean
transaortic gradients decreased from 76.3  33.0 mm Hg and 45.2  20.6 mm Hg at baseline to 21.8  8.4
mm Hg and 11.7  4.8 mm Hg post-procedure, respectively, both p  0.0001. Mean indexed effective orifice
area (IEOA) increased from 0.35  0.10 cm2/m2 at baseline to 0.90  0.18 cm2/m2 post-procedure, p 
0.0001. Severe prosthesis–patient mismatch (IEOA 0.65 cm2/m2) occurred in 2 patients (5.9%). At a mean
follow-up of 14  11 months, gradients remained low and 30 of the 31 remaining survivors were in New York
Heart Association functional class I or II.
Conclusions In high-risk patients with severe AS and a small aortic annulus, TAVI is associated with good post-procedural
valve hemodynamics and clinical outcomes. TAVI may provide a reasonable alternative to conventional AVR in
elderly patients with a small aortic annulus. (J Am Coll Cardiol 2011;58:1016–24) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.026Aortic valve replacement (AVR) in patients with severe
aortic stenosis (AS) and a small aortic annulus has been
associated with a high incidence of prosthesis–patient mis-
match (PPM) (1–3). PPM has in turn been associated with
diminished extent of regression of left ventricular hypertro-
phy, reduced coronary flow reserve, increased incidence of
congestive heart failure, diminished functional capacity, and
increased risk of early and late mortality (4–7). In order to
allow implantation of an appropriately sized prosthetic valve
and prevent PPM in a patient with a small aortic annulus,
an aortic annular enlargement procedure or a complete
replacement of the aortic root may be necessary at the time
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accepted May 31, 2011.of AVR. These procedures significantly enhance the com-
plexity of the operation, and may increase morbidity and
mortality, especially in elderly patients (8,9).
Transcatheter aortic valve implantation (TAVI) has
emerged as an alternative to AVR in high-risk patients with
AS (10–12), and implanted prostheses perform well com-
pared with currently available surgical valves with respect to
relief of aortic stenosis and post-procedural valve hemody-
namics (13). However, no specific data exist on the results of
TAVI in patients with a small aortic annulus. In this study,
we sought to examine prosthetic valve hemodynamics, as
well as early and midterm outcomes of patients with a small
aortic annulus who underwent TAVI at our institution.
Methods
Patient population. We identified all patients with severe,
symptomatic, native-valve AS and an aortic annular diam-
eter 20 mm who underwent TAVI either by a transfemo-
ral or transapical approach at our institution. Patients that
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conventional surgery by consultant cardiac surgeons. All
patients were initially evaluated for the feasibility of a
transfemoral approach; a transapical approach was ulti-
mately selected in the setting of a prohibitively small or
diseased iliofemoral arterial tree, and in the presence of
mobile plaque, excessive calcification, or extreme tortuosity
of the descending thoracic aorta and/or aortic arch. Further
details regarding patient selection, use of a transfemoral
versus transapical approach, and procedural technique have
been previously published (12–14). All patients provided
written informed consent, and the study was in compliance
with our institutional research ethics board. Preoperative
characteristics including patient demographics, cardiovascu-
lar risk factors, and comorbid medical illnesses, as well as
procedural and post-operative data, were prospectively col-
lected by dedicated personnel and entered into a registry. All
patients received a 23-mm Edwards SAPIEN bioprosthesis
(Edwards Lifesciences, Inc., Irvine, California). Procedural
success was defined as the successful implantation of a
functioning prosthesis within the aortic annulus, without
procedural mortality or conversion to sternotomy. Longitu-
dinal follow-up was obtained by outpatient clinic visit
and/or telephone contact at 6 and 12 months post-
procedure and yearly thereafter.
Doppler echocardiography. Aortic annulus diameter was
measured preoperatively using transesophageal echocardi-
ography (TEE) in the long-axis, mid-esophageal view, from
leaflet insertion to leaflet insertion in mid-systole (15).
Post-procedural prosthetic transvalvular pressure gradients
and effective orifice area (EOA) were measured prior to
hospital discharge and at 6 and 12 months post-procedure
and yearly thereafter. The left ventricular outflow tract
diameter was measured immediately proximal (ventricular)
to the valve prosthesis stent insertion site for calculation of
the post-procedural EOA by the continuity equation (16).
EOA was indexed for the patient’s body surface area. Severe
PPM was defined as an indexed EOA (IEOA) 0.65
cm2/m2, and moderate PPM was defined as an IEOA
between 0.65 and 0.85 cm2/m2 (2,17). Post-procedural
aortic insufficiency (AI) was classified as paravalvular, trans-
valvular, or mixed, depending on the origin of the regurgi-
tant jet(s). The severity of regurgitation was graded as mild,
moderate, or severe (18).
Statistical analysis. Statistical analysis for the study was
performed using Statistical Analysis System (SAS) software
version 9.2 (SAS Institute, Inc., Cary, North Carolina).
Continuous variables were expressed as mean  SD and
were compared using paired t tests or nonparametric equiv-
alents where appropriate. Mixed effects modeling was used
to determine the statistical significance of transaortic gradi-
ents and aortic valve areas at different time periods. An
unrestricted covariance structure was used to measure the
dependence among repeated measurements. The multi-
variate normality assumptions were verified with the
Shapiro-Wilk test after a Cholesky factorization. Cate-gorical variables were expressed
as percentages. Mixed effects
ordinal regression was per-
formed to test for significant
changes in AI over time. All-
cause mortality at mid-term
follow-up was evaluated using
the Kaplan-Meier technique. All
p values were 2-sided, and differ-
ences were considered statisti-
cally significant when p  0.05.
Results
Between April 2007 and July
2010, 164 patients with severe
symptomatic AS underwent
TAVI at our institution. Exclud-
ing patients with failed biopros-
thetic aortic prostheses, a total of
68 patients received a 23-mm
valve, and among these, 35 patients (51.5%) with an aortic
annular diameter 20 mm (mean 18.5  0.9 mm, range 16
to 19.5 mm) were identified (Fig. 1). Eleven patients
underwent a transfemoral approach (31.4%), and the re-
mainder underwent a transapical procedure. Reasons for
selecting a transapical approach were small iliofemoral
arteries (n  18), extensive thrombus or mobile atheroscle-
rotic plaque in the abdominal or thoracic aorta (n  4),
horizontal ascending aorta (n  1), and extreme tortuosity
of the descending thoracic aorta (n  1). The mean age of
patients was 79.2  9.4 years, ranging from 55 to 96 years.
Eleven patients (31.4%) had undergone previous cardiac
surgery (coronary artery bypass graft surgery in 10 patients,
mitral valve replacement in 1 patient). Other baseline
clinical and echocardiographic characteristics of the patient
cohort are shown in Table 1.
Procedural success was achieved in all but 1 patient
(97.1%). This patient was a 96-year-old female with a
severely calcified aortic valve, severe pulmonary hyperten-
sion, and logistic EuroSCORE of 70.6. Transapical TAVI
was complicated by residual post-procedural moderate para-
valvular aortic regurgitation and left ventricular apical bleed-
ing requiring surgical repair with multiple pledgeted sutures.
Delayed balloon aortic valvuloplasty was performed, but the
patient remained in cardiogenic shock leading to death on
the third post-operative day. Autopsy revealed a large
anteroapical myocardial infarction that was likely iatrogenic,
related to the left ventricular apical repair, given the absence
of coronary artery disease on preoperative coronary angiog-
raphy. This was the only in-hospital death. This patient was
excluded from subsequent analyses of post-procedural pros-
thetic valve hemodynamics.
Major procedural and 30-day complications were severe
paravalvular aortic regurgitation requiring implantation of a
Abbreviations
and Acronyms
AI  aortic insufficiency
AS  aortic stenosis
AVR  aortic valve
replacement
CI  confidence interval
EOA  effective orifice
area
IEOA  indexed effective
orifice area
NYHA  New York Heart
Association
PPM  prosthesis–patient
mismatch
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiographysecond 23-mm Edwards SAPIEN prosthesis within the
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TAVI and Small Aortic Annulus August 30, 2011:1016–24pre-existing prosthesis (“valve-in-valve”) with subsequent
improvement of AI to mild grade (n  1), third-degree
trioventricular block requiring permanent pacemaker (n 2),
nd acute renal failure (n  3) (Table 2). Access-site
omplications occurred in 3 patients: 1 patient with left
nterior mini-thoracotomy wound infection following
ransapical TAVI, another patient with a groin wound
nfection following transfemoral TAVI, and a third patient
equiring surgical reconstruction of a torn right common
emoral artery following transfemoral TAVI. There were no
nnular ruptures, acute aortic dissections, or coronary oc-
lusions, no conversions to sternotomy, and in no case was
ardiopulmonary bypass or extracorporeal circulation insti-
uted for hemodynamic instability.
chocardiographic data. Peak and mean transaortic gra-
ients decreased from 76.3 33.0 mm Hg and 45.2 20.6
mm Hg at baseline to 21.8  8.4 mm Hg and 11.7  4.8
mm Hg post-procedure, respectively, both p  0.0001.
Mean EOA increased from 0.55  0.15 cm2 at baseline to
1.41  0.25 cm2 post-procedure, p  0.0001. Mean IEOA
ost-procedure was 0.90  0.18 cm2/m2. Severe PPM
(IEOA 0.65 cm2/m2) occurred in 2 patients (5.9%), and
oderate PPM (IEOA 0.65 to 0.85 cm2/m2) was observed
in 11 patients (32.4%) (Fig. 2). Aortic insufficiency follow-
ing TAVI occurred in 25 patients (71.4%), most of which
had trace insufficiency (18 of 25 patients). Mild AI was
present in 6 patients (17.1%), and moderate insufficiency
was seen in 1 patient who later died on post-operative day
3 in cardiogenic shock due to a large anteroapical myocar-
dial infarction (the patient described in the previous text).
The insufficiency was paravalvular in 16 of 25 patients,
Figure 1 Aortic Annulus Diameters
The distribution of aortic annular diameters, as measured on pre-operative transestransvalvular in 8 patients, and mixed in 1 patient. 7Midterm clinical outcomes and echocardiographic
data. At a mean follow-up of 14.4  11.1 months (maxi-
mum 3 years), 12 patients (35.3%) were readmitted to
hospital at a mean of 10.8  9.5 months following the
rocedure. Causes of hospital readmission were broncho-
leural pneumonia (n 3), congestive heart failure (n  3),
astrointestinal bleeding (n  3), myocardial infarction
n  2), and symptomatic atrial fibrillation (n  1). During
he follow-up period, there were 3 deaths at 1, 16, and 24
onths post-procedure. Using Kaplan-Meier methodology,
he 1- and 2-year probabilities of survival were 94.3% (95%
onfidence interval [CI]: 79.5% to 99.0%) and 76.2% (95%
I: 60.2% to 89.4%), respectively (Fig. 3). Causes of death
ere cardiac (sudden death) in 1 patient and noncardiac in
patients (metastatic lung cancer and bronchopleural pneu-
onia, respectively). All remaining survivors were in New
ork Heart Association (NYHA) functional class I or II,
xcept for 1 patient in class III due to severe pre-existing
ulmonary disease requiring home oxygen. Outpatient
ransthoracic Doppler echocardiography at 6, 12, and 24
onths revealed persistently low transprosthetic gradients
nd durable relief of AS among patients with aortic annular
iameter 20 mm (Fig. 4A). Transprosthetic gradients and
alve areas both early and late post-procedure were compa-
able to a contemporaneous group of 33 patients with aortic
nnular diameter20 mm (range 20 to 22 mm, mean 20.5
.7 mm) who received a 23-mm Edwards SAPIEN pros-
hesis for native-valve AS during the study period (Fig. 4B).
he prevalence of AI was significantly lower at 6 months
ompared with immediately post-procedure (40.7% vs.
eal echocardiography, are shown (n  35).ophag1.4%, respectively, p  0.013). Aortic regurgitation re-
D
m
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(Fig. 5).
Discussion
In our study of 35 high-risk patients with severe AS and a
small (20 mm) aortic annulus, including 14 patients with
annuli 19 mm in diameter, TAVI was associated with
good periprocedural and mid-term outcomes, with 1 peri-
operative death (2.9%) and no patient requiring conversion
to sternotomy or extracorporeal circulation. Post-procedural
peak and mean transvalvular pressure gradients were signif-
icantly reduced, with a relatively low (5.9%) incidence of
severe PPM. Trace AI was observed in 18 patients (51.4%),
mild in 6 patients (17.1%), and moderate in 1 patient
(2.9%). At a mean follow-up of 14 months, there was no
appreciable deterioration of transprosthetic gradients and
valve areas, and AI completely disappeared in 8 patients at
6-month follow-up. All but 1 patient were in NYHA
functional class I or II, demonstrating a lasting salutary
effect of TAVI in this patient population.
Surgical management of the small aortic annulus. The
Baseline Characteristics ofthe Study Population (n  35)Table 1 B sel ne Characteristics ofthe Study Population (n  35)
Age, yrs 79.2 9.4
Female 33 (94.3%)
Body mass index, kg/m2 25.4 4.3
Diabetes mellitus 11 (31.4%)
Hypertension 33 (94.3%)
Hyperlipidemia 28 (80%)
Chronic obstructive pulmonary disease 6 (17.1%)
Chronic renal failure 21 (60%)
Glomerular filtration rate, ml/min* 53.3 21.7
Frailty 8 (22.9%)
Porcelain aorta 12 (34.3%)
NYHA functional class III or IV 33 (94.3%)
Cerebrovascular disease 10 (28.6%)
Atrial fibrillation 10 (28.6%)
Coronary artery disease 21 (60%)
Previous PCI 12 (34.3%)
Previous sternotomy† 11 (31.4%)
Logistic EuroSCORE 18.8 14.1
Society of Thoracic Surgeons’ score 7.5 3.6
Echocardiographic data
Left ventricular ejection fraction, % 59 13
Left ventricular ejection fraction 40% 3 (8.6%)
Pulmonary artery systolic pressure 60 mm Hg 8 (22.9%)
Aortic annulus diameter, mm 18.5 0.9
Aortic transvalvular pressure gradient
Maximum, mm Hg 76.3 33.0
Mean, mm Hg 45.2 20.6
Aortic valve orifice area, cm2 0.55 0.15
Aortic valve indexed effective orifice area, cm2/m2 0.35 0.10
Values are mean  SD or n (% of the total). *Estimated using the Modification of Diet in Renal
isease (MDRD) formula. †Previous coronary artery bypass graft surgery in 10 patients, previous
itral valve replacement in 1 patient.
NYHA  New York Heart Association; PCI  percutaneous coronary intervention.presence of a small aortic annulus poses a considerablechallenge in the management of patients with severe AS
undergoing AVR. The optimal approach to these patients
remains controversial. During AVR, an aortic annular
enlargement procedure may be necessary (19,20). Recent
retrospective studies (8,9,21) have shown excellent results
associated with annular enlargement procedures, with little
operative morbidity and mortality in selected patients,
although few data are published in elderly, high-risk pa-
tients, possibly reflecting surgical reluctance to go ahead
with these procedures in the nonoptimal patient. In a study
by Dhareshwar et al. (8), the patients that underwent aortic
annular enlargement were younger and had better left
ventricular function than the patients undergoing stan-
dard AVR. Despite this, operative mortality was nearly
doubled in the annular enlargement patients (5.6% vs.
2.9%, p  0.03), although there was no independent
effect of annular enlargement on mortality on multivari-
ate analysis.
Other potential management options of the small aortic
annulus during AVR include the implantation of smaller-
sized mechanical valves (22,23) or stentless bioprostheses
(24,25). However, bleeding risks may be 20 times higher
among elderly patients with mechanical compared with
biological valves (26), generally limiting the use of mechan-
ical valves to younger patients (27,28). Furthermore, the
hemodynamic superiority of stentless aortic bioprostheses
continues to be debated, with available studies reporting
conflicting data, both for normal (24,25,29) and small-
sized aortic annuli (30 –32). Our center published its
Procedural Variables andIn-Hospit Outcomes (n  35)Table 2 P ocedur l Variables andIn-Hospital Outcomes (n  35)
Approach
Transapical 24 (68.6%)
Transfemoral 11 (31.4%)
Procedural success 34 (97.1%)
Conversion to sternotomy 0
Use of extracorporeal circulation 0
In-hospital clinical outcomes
Mortality 1 (2.9%)
Stroke 0
New-onset acute renal failure 3 (8.6%)
Red blood cell transfusion 19 (54.3%)
Permanent pacemaker 2 (5.7%)
Wound infection 2 (5.7%)
Length of hospital stay, days 6 (5–10)
Echocardiographic data
Aortic insufficiency* 25 (71.4%)
Post-procedural aortic transvalvular pressure gradient†
Maximum, mm Hg 21.8 8.4
Mean, mm Hg 11.7 4.8
Post-procedural aortic valve effective orifice area, cm2† 1.41 0.25
Post-procedural aortic valve indexed effective orifice area,
cm2/m2†
0.90 0.18
Values are n (% of the total), mean SD, or median (interquartile range). *Trace or mild except in
1 patient with moderate paravalvular aortic regurgitation requiring delayed balloon aortic valvulo-
plasty. †Gradients and valve area measured on pre-discharge transthoracic Doppler
echocardiography.
o
(
a
s
(
J
C
i
a
h
w
r
a
t
u
M
f
l
w
a
1020 Kalavrouziotis et al. JACC Vol. 58, No. 10, 2011
TAVI and Small Aortic Annulus August 30, 2011:1016–24experience of over 400 implantations of the Freestyle
stentless bioprosthesis (Medtronic, Inc., Minneapolis,
Minnesota), among which 68 patients received a 19-mm
or 21-mm prosthesis inserted with a subcoronary tech-
nique (32). The incidence of severe PPM was 58% and
17% for the 19- and 21-mm prostheses, respectively. A
complete aortic root replacement technique may over-
come the limitations associated with a subcoronary im-
plantation within the otherwise unmodified aortic root.
Figure 2 Incidence of Post-Procedural Prosthesis–Patient Mism
Effective orifice area was measured on pre-discharge transthoracic Doppler echoca
of prosthesis–patient mismatch. The number below each bar graph corresponds to th
IEOA  indexed effective orifice area; PPM  prosthesis–patient mismatch.
Figure 3 Survival Following Transcatheter
Aortic Valve Implantation
Kaplan-Meier freedom from all-cause mortality during follow-up among patients
with aortic annular diameter 20 mm.iHowever, this approach has been associated with high
morbidity and mortality in elderly patients (33).
Hemodynamic performance and clinical outcomes
following TAVI. To the best of our knowledge, this is the
first study to systematically examine the results of TAVI
with the Edwards SAPIEN valve in patients with a small
aortic annulus. The post-procedural mean transprosthetic
gradient of 11.7 mm Hg and EOA of 1.41 cm2 observed in
ur study are similar to those reported in the PARTNER
Placement of Aortic Transcatheter Valves) trial (11.4 mm Hg
nd 1.5 cm2, respectively), which included 26-mm prosthe-
es (34). Also, the incidence of moderate (32.4%) and severe
5.9%) PPM in our study is similar to that reported by
ilaihawi et al. (35) after implantation of the Medtronic
oreValve prosthesis (moderate PPM in 32%, severe PPM
n 2% of patients). However, only patients with an aortic
nnular diameter 20 mm were evaluated in that study.
Clavel et al. (13) recently published a study examining the
emodynamic performance of Cribier-Edwards and Ed-
ards SAPIEN valves. TAVI patients were matched with
espect to several variables, including body surface area,
ortic annular diameter, and left ventricular ejection frac-
ion, to a group of surgical patients that underwent AVR
sing stented pericardial valves (Edwards Perimount
agna) and stentless Medtronic Freestyle valves. The authors
ound that mean transprosthetic gradients were significantly
ower among the TAVI patients (10  4 mm Hg), compared
ith patients receiving stented valves (13 5 mm Hg), as well
s those receiving stentless bioprostheses (14  6 mm Hg). It
aphy and was indexed to patient body surface area in order to define categories
ient’s pre-procedural aortic annular diameter according to the inset table on right.atch
rdiogr
at pats noteworthy that differences between mean gradients were
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August 30, 2011:1016–24 TAVI and Small Aortic Annulusmore pronounced among the subgroup of patients with annu-
lar diameters 20 mm, and any hemodynamic benefit associ-
ted with TAVI was lost in those patients with larger annuli.
istention of the aortic annulus due to systematic over-sizing
nd the absence of a sewing ring have been suggested as some
f the possible mechanisms explaining the superior hemody-
Figure 4 Transaortic Pressure Gradients and Aortic Valve Area
Mean transvalvular pressure gradients and aortic valve areas (mean  SD) are
those of a contemporaneous cohort of patients with annuli 20 mm who recei
mean gradients and aortic valve areas did not differ between patients with an
ods). *p  0.0001. **p  NS.amic profile associated with TAVI compared with standard aurgical valves (13). In light of these data, our results suggest
hat the hemodynamic advantage of the Edwards SAPIEN
rosthesis is maintained in small and very small (19 mm)
nnuli, and there appears to be no deleterious effect on both
linical and hemodynamic outcomes following the deployment
f a fixed-sized 23-mm prosthesis within a small, calcified
aseline and Post-Procedure
n over time for patients with an aortic annular diameter 20 mm (A), and
23-mm Edwards SAPIEN valve during the study period (B). Post-procedural
annulus 20 mm and those with annuli 20 mm (p  NS for all time peri-s at B
show
ved a
aorticortic annulus.
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TAVI and Small Aortic Annulus August 30, 2011:1016–24Post-procedural AI was observed in over two-thirds of
our patients and is consistent with the rates reported in
recent literature (14,34). However, the incidence of signif-
icant AI that is moderate or greater was lower in our series
compared with recent studies. In our series, only 1 patient
(2.9%) had moderate or greater AI post-TAVI compared
with 12% in the PARTNER trial (34) and 6% in the
multicenter Canadian study (14). These results are concor-
dant with those of a recent report from Détaint et al. (36),
in which significant paravalvular AI that is moderate or
greater was never observed in patients with an aortic annulus
22 mm, suggesting that smaller annuli may minimize
prosthesis–annulus incongruity and may allow for a better
“fit” and more complete apposition of the balloon-
expandable prosthesis against the aortic annulus.
In high-risk patients with severe AS and a small aortic
annulus, our results suggest that TAVI is associated with
good clinical outcomes, with a 30-day mortality of 2.9% and
Figure 5 Incidence of Post-Procedural Aortic Insufficiency
The proportion of patients without aortic regurgitation was significantly higher at 6
(59.3% vs. 28.6%, respectively, p  0.013). No other substantial change in aortic1- and 2-year survival rates of 94% and 76%, respectively.Survival in our study was better than that reported in
previous TAVI studies (11,14,34), and might be partially
related to the slightly lower risk profile of our study
population as evaluated by the logistic EuroSCORE (mean
of 19%) and the Society of Thoracic Surgeons’ score (mean
of 7.5%). However, more than one-third of the patients
included in our study had porcelain aorta as the main
comorbidity determining patient inoperability, a risk factor
not included in conventional surgical risk scoring systems.
In addition, no cases of aortic annulus rupture were ob-
served in this study. The potential risk of aortic annulus
rupture due to excessive valve prosthesis over-dimensioning
in patients with a small aortic annulus has been reported
(37,38). The use of under-sized balloons for balloon valvu-
loplasty prior to TAVI may be important to reduce this
potential life-threatening complication.
Study limitations. First, this is a small, single-center series
without a comparative group. However, the aim of this
s compared with immediately post-procedure
gitation was observed during follow-up.month
regurdescriptive study was to evaluate the feasibility and safety of
1023JACC Vol. 58, No. 10, 2011 Kalavrouziotis et al.
August 30, 2011:1016–24 TAVI and Small Aortic AnnulusTAVI in an elderly cohort of patients with severe aortic
stenosis and a small aortic annulus who are unsuitable for
standard AVR due to prohibitive risk. Also, the relatively
short duration of follow-up limits our ability to make
meaningful statements about the long-term performance
and durability of the Edwards SAPIEN prosthesis in the
small aortic root, and further longitudinal analysis is war-
ranted. Another limitation relates to the use of TEE to
measure the aortic annular diameter. TEE may underesti-
mate aortic annular diameter compared to multislice com-
puted tomography (39). However, TEE-based annular
measurements are extensively used in TAVI studies, includ-
ing the PARTNER trial (34), and have been associated
with good clinical results post-TAVI (15). In the absence of
a gold standard, TEE remains the imaging modality of
choice for aortic annular assessment prior to TAVI in most
centers.
Conclusions
Among high-risk patients with severe AS and a small aortic
annulus, TAVI is associated with good in-hospital and
mid-term outcomes, and post-procedural valve echocardio-
graphic performance, with a relatively low incidence of
severe PPM. TAVI in these patients compares favorably
with currently available surgical options, and may provide a
reasonable alternative to conventional AVR in elderly pa-
tients with a small aortic annulus.
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